UK-based, Dxcover (previously Clinspec Diagnostics) is a clinical-stage diagnostics company. The startup has developed a liquid biopsy platform - powered by “attenuated total reflectance, fourier transform infrared spectroscopy” “of pan-omic biomarkers” - which analyzes patient blood samples (with the help of AI) to detect the presence (or absence) of cancer. It generates compelling clinical data with high accuracy detection (80-90%) of Stage I & II brain tumors, particularly Glioblastoma Multiforme (the most aggressive type). The firm has also published data with “exceptional potential” on detecting pancreatic cancer as well as 6 other types (lung, colon, breast, prostate, ovarian & kidney) (the 8-types combined, account for 65% of the global cancer burden). Various patents have already...

The global paint & coatings market (usually divided into cleaning & pretreatment, paint, and equipment vendors) is valued at $184bn (60% accrues to the industrial sector) & projected to reach $212bn by 2026 (for comparison - or to give away my true nature - that’s about as large as the global video games market). So, in comes France-based Ecoat, which develops, manufactures & sells bio-based/ solvent-free “binders” to paint & coating manufacturers. Its binders can make formulations a) chemical resistant e.g. anti-corrosion/ water repellent, b) fast drying/ drier free/ quickly recoatable – based on its proprietary “Leaf Tech” technology, c) low tack, d) low yellowing, e) low VOC & odorless – based on its proprietary...